IER3-AS1

Across TCGA pan-cancer cohorts, IER3-AS1 RNA differs between tumor and matched normal tissue in 10 of 18 cancer types tested, making tumor–normal expression one of IER3-AS1’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where IER3-AS1 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types IER3-AS1 is over-expressed in tumor, although a few such as BLCA and KIRC show the opposite, repressed pattern.

LIHC, LUAD, and BLCA are the cancer types where IER3-AS1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in IER3-AS1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	Female	II,III,IV	+1.018	<.001	9	view →
LUAD	Female	III,IV	+0.976	<.001	7	view →
BLCA	All	All	−0.738	.010	6	view →
BRCA	All	All	+0.494	<.001	6	view →
KIRC	All	All	−0.216	.013	6	view →
KICH	All	All	−0.408	.004	5	view →
ESCA	All	All	+0.552	.014	4	view →
LUSC	Male	All	+0.542	<.001	3	view →
THCA	Male	IV	−0.773	.001	2	view →
CHOL	All	All	+0.766	.002	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 10 strongest of 10 lineages.

IER3-AS1–LIHC

Open the LIHC breakdown →